Manufacturer drug pricing has been and will continue to be a key focal point on political agendas. But as proposed legislation is blocked or stymied, will there be any room for advancement? Andy Cournoyer discusses potential roadblocks, opportunities for innovation, and what they mean for payers in 2020.
Access Experience Team member Andrew Cournoyer looks at national health plans and the growing trend toward vertical integration and management of drugs covered under the medical benefit.
Andrew Cournoyer outlines recent Medicare regulatory changes likely to influence formulary offerings and emphasizes the trend toward patient affordability and drug pricing in 2020 formulary design.
Drug costs are a main concern for both government and commercial payers. In 2018, CMS tackled drug costs in Medicare through several measures. Will the trend continue in 2019? Meanwhile, the use of ICER’s value framework to inform commercial payer decision makers is increasing. Are value- and outcomes-based strategies more important?
Recent legislative actions by CMS have taken aim at the current Medicare structure, with negotiating leverage at the center of the initiatives. Arguably the primary target of these actions is the drug manufacturer. Andrew Cournoyer addresses the need for allied partnerships between payers and manufacturers as a way to navigate the increasingly complex landscape.
What will the American Patients First initiative mean for payers? Will it deliver on lowering drug prices and improving affordability for patients? Andrew Cournoyer, Vice President, Payer Access Solutions, addresses these questions as he breaks down what we know and don’t know about the Trump administration’s recent announcement.
Ami Gopalan and Andrew Cournoyer from our Payer Access Solutions team present key takeaways from their recent AMCP Nexus presentation on the variable use of external sources of data. The authors also share findings from Precision’s latest proprietary Rapid Pulse™ survey, highlighting new opportunities for both payers and manufacturers to pursue in the development and evaluation of evidence to support formulary decision-making.